Latest News about Pasithea Therapeutics Corp/
Recent news which mentions Pasithea Therapeutics Corp/
From Benzinga
 
   New Drugs And Therapies Are Giving MS And ALS Sufferers New Hope
   
  
  
  
 October 10, 2022
  
   New Drugs And Therapies Are Giving MS And ALS Sufferers New Hope
   
  
  
  October 10, 2022
  From Benzinga
 
   Biotech Company Pleased With Results Of Early Testing Demonstrating Vaccine Potential For Multiple Sclerosis
   
  
  
  October 03, 2022
  From Benzinga
 
   Smaller Biotechs May Pave Way For New Generation Of Therapeutics For Hard-to-Treat Neurological Disorders
   
  
  
  August 08, 2022
  From Benzinga
 
   A Monoclonal Antibody Treatment For ALS Could Begin Human Trials By 2023, According To Pasithea
   
  
  
  July 28, 2022
  From Benzinga
 
   Pasithea Therapeutics Receives AUD $1 Million Research Award Following Recent Acquisition
   
  July 18, 2022
  Tickers 
   KTTA
  
  
  From Benzinga
 
   Pasithea Reveals Cash Position Of $52.9 Million In Latest Earnings Report, To Expand Pipeline And Fund Operations Well Into 2024
   
  April 01, 2022
  Tickers 
   KTTA
  
  
  From Benzinga
 
   Pasithea Partners With Glimpse Group To Co-Develop VR Environments For Patients With Psychiatric Disorders
   
  
  
  March 10, 2022
  From Benzinga
 
   Pasithea Therapeutics Announces Plans To Open Three New Clinics In The UK By Mid-2022
   
  February 24, 2022
  Tickers 
   KTTA
  
  
  From Benzinga
 
   From Mobile Clinics to Drug Development, This Company Is Attempting to Tackle Brain Disorders and Promote Mental Health Advances
   
  
  
  January 05, 2022
  From Benzinga
 
   EXCLUSIVE: Pasithea Clinics Launches In-Home Intravenous Ketamine Therapy In Major US Cities
   
  November 17, 2021
  Tickers 
   KTTA
  
  
  From Benzinga
 
   Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
  
  
 Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
  © 2025 FinancialContent. All rights reserved.
 
